URGENT PANDEMIC INFORMATION

In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List


Gene Therapy Immunogenicity - Virtual Summit


Date
Aug 04, 2021 - 08:00 AM - Aug 05, 08:00 AM
Organizer
Hanson Wade
Venue
online
Location
Online, Online

Online,
Online,
USA,
ZIP: 00000
Phone: +442031418700

Ticket Price: Conference Ticket (1st Release): USD 1399.0, Conference Ticket (2nd Release): USD 1599.0, Conference Ticket (3rd Release): USD 1799.0, Conference Ticket (Final Release): USD 1999.0

Immunogenicity compromises both the efficacy and safety of gene therapies and thus represents one of the most prominent challenges that must be overcome in the field. Uniting translational, clinical, regulatory and manufacturing gene therapy functions, the inaugural Gene Therapy Immunogenicity Summit is the industry's definitive meeting enabling you to better measure, modulate and predict immune response and drive transformative treatments through the clinic to patients more quickly and efficiently.

Key topics of discussion include:
Evaluating the suitability and success of current immunosuppression agents in the context of gene therapy
Employing risk assessment tools to develop clinical bioanalytical and immunogenicity monitoring strategies
Dissecting the immunogenicity of gene therapy vectors to better understand immunology safety concerns
Better understanding the innate immune response and its implications for gene therapy transduction
Evaluating the resolution and throughput of technologies to define empty vs full capsid presence
Implementing the use of preclinical risk assessment tools to drive clinical immunogenicity strategies for gene therapy modalities
What the implications are for the safety and efficacy of gene therapies if re-dosing is to occur

URLs:
Tickets: https://go.evvnt.com/614539-2?pid=1052
Brochure: https://go.evvnt.com/614539-3?pid=1052


Speaker Details


Barry Byrne, Professor and Associate Chairman, University of Florida, Mark Milton, Area Head of Ophthalmology, Novartis, Sander van Deventer, Executive Vice President, uniQure, Martin Childers, Chief Medical Officer, Asklepios BioPharmaceutical, Roland Herzog, Professor of Pediatrics, Indiana University School of Medicine, Klaudia Kuranda, Immunology Leader, Spark Therapeutics, David Favre, Vice President Translational Medicine, Asklepios BioPharmaceutical, Boris Gorovits, Senior Director, Pfizer, Genine Winslow, Founder and Chief Executive Officer, Chameleon Biosciences, Rune Kjeken, Director - Technical and Advanced Therapies, Norwegian Medicines Agency, Takashi Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc., Brian Long, Associate Director, BioMarin, Casey Case, President Research and Development, 4D Molecular Therapeutics, Ying Kai Chan, Chief Scientific Officer, Allyx Therapeutics, Pierre Burguiere, Director - Analytical Development and Nonclinical Research, GenSight Biologics, Korinna Henseleit, Senior Bioanalytical Scientist, Biogen, Tony Arulanadam, Vice President and Head of Gene Therapy Nonclinical Research, PTC Therapeutics, Yanmei Lu, Senior Director Bioanalytical Sciences, Sangamo Therapeutics, Roberto Calcedo, Vice President Immunology and Safety, TouchDown Therapeutics, Andrew Melton, Senior Scientist II, BioMarin, Carsten Bonnemann, Senior Investigator, NIH, Liching Cao, Director Bioanalytical Operations, Sangamo

Event Categories
Keywords: pharmaceutical , Medicine




Comments








Events Calendar

SunMonTueWedThuFriSat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31 1 2 3 4

Newsletters

VIP Life Time Subscription to our Newsletters!
$399.99
$299.99